National Treatment Principle (GPA)

The National Treatment Principle is one of the two core non-discrimination obligations at the heart of the WTO Government Procurement Agreement. It prohibits covered contracting authorities from treating foreign suppliers, goods, or services less favourably than their domestic equivalents. Together with the non-discrimination principle, it creates the legal foundation for meaningful cross-border competition in public procurement.

What is the National Treatment Principle (GPA)?

Article IV of the revised GPA requires each GPA party to accord, with respect to covered procurement, treatment no less favourable than that accorded to domestic goods, services, and suppliers. This has several practical dimensions:

Qualification requirements. A contracting authority cannot require foreign suppliers to hold a domestic registration, certification, or licence that is not also required of domestic suppliers, unless the domestic requirement is genuinely necessary and proportionate. Requiring a Belgian company to be registered with a French chamber of commerce as a condition of tendering for a French contract, when French companies are not subject to an equivalent requirement, would breach national treatment.

Technical specifications. Specifications drafted around domestic standards, proprietary systems, or locally-sourced components can effectively exclude foreign suppliers without any explicit nationality criterion. The GPA prohibits such disguised discrimination. Specifications must be based on performance or functional characteristics, or on international standards where available, rather than national standards that foreign suppliers cannot readily meet.

Tender procedures. The timelines, notice periods, languages, and documentary requirements applied to a procurement must not in practice disadvantage foreign suppliers. Extremely short tender periods, notices published only in an obscure domestic register, or documentation requirements that impose disproportionate burdens on non-resident suppliers can all constitute breaches of national treatment.

Evaluation and award. The national treatment obligation extends to the evaluation stage. A buyer cannot apply evaluation criteria that effectively favour domestic suppliers, such as preference points for local content or domestic headquarters, unless a specific general note in its coverage schedule permits such a measure.

Why it matters for bidders

For European suppliers bidding in non-EU GPA markets, the national treatment principle is the primary legal lever. If a US federal agency uses a specification that references a domestic military standard unavailable to foreign manufacturers, or if a Japanese ministry applies a qualification process that requires a Japanese corporate registration without equivalent substance, these may be challengeable under the principle.

Conversely, the principle protects non-EU GPA-party suppliers bidding into European markets. An EU contracting authority cannot apply "buy European" preferences, offset requirements, or local-content conditions in covered procurement without a clear legal basis in an agreed general note. EU Directive 2014/24/EU already implements this requirement for domestic EU law, and the GPA extends the same protection to suppliers from GPA parties such as the UK, Norway, Switzerland, and others.

Example

A South Korean IT firm bids on an Austrian federal agency software contract. The agency's specifications require compliance with a specific Austrian national standard for which no international equivalent exists and which the Korean supplier cannot practicably certify within the tender period. If the standard was chosen without a genuine technical justification and effectively functions as a barrier to foreign suppliers, this may constitute a breach of the national treatment obligation. The Korean supplier can raise this through Austria's challenge procedures or bring it to the attention of the Korean government for potential WTO-level engagement.

Frequently Asked Questions

Does national treatment mean foreign and domestic suppliers must receive identical treatment?

Not necessarily identical, but no less favourable overall. A contracting authority may have legitimate procedural differences that flow from administrative necessity, such as requiring translations of documents into the official language of the jurisdiction. What is prohibited is treatment that is less favourable in substance, meaning treatment that materially disadvantages foreign suppliers relative to their domestic counterparts without justification.

Can buy-local preferences ever coexist with the national treatment principle?

Yes, if they are explicitly notified and permitted under a party's Annex 7 general notes. Some GPA parties maintain notified carve-outs for small business set-asides, regional development measures, or specific public interest programmes. Outside such agreed carve-outs, buy-local preferences in covered procurement breach national treatment and are not permitted.

How does national treatment interact with the EU's internal market rules?

EU single market rules provide national treatment among EU member states even below GPA thresholds and for entities not covered by the directives, through the principles of non-discrimination and transparency derived from the Treaty on the Functioning of the European Union. The GPA national treatment obligation adds an additional layer for suppliers from non-EU GPA parties in above-threshold covered procurement.